Vera Clinic, internationally recognised as a leading centre of innovation in hair restoration surgery, has released the full ...

The FDA has approved Otarmeni, the first-ever gene therapy for genetic hearing loss caused by the OTOF gene, for both ...

In a significant step towards strengthening surveillance and rapid response to vector-borne diseases, the health & family welfare (H&FW) department has established a dedicated state control room under ...

The big five hyperscalers plan to spend a total of more than $700 billion on artificial intelligence (AI) infrastructure this ...

The U.S. Food and Drug Administration today approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy. Otarmeni is indicated for the ...

MeiraGTx Holdings (NASDAQ:MGTX) is one of the best growth stocks under $10 to invest in. On April 16, MeiraGTx Holdings ...

Supported by the CHORD trial, this AAV vector-based therapy delivers a working copy of the OTOF gene and restores otoferlin ...

Three Philadelphia scientists won a $3 million Breakthrough Prize for developing the first FDA-approved gene therapy for a genetic disease, prize sponsors announced Saturday. Their work created a ...

Neuronal specification, expansion and differentiation are tightly regulated by the concerted actions of transcription and chromatin modifying factors that are recruited to regulatory elements in the ...

Approval in severe-to-profound and profound OTOF -related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of ...

Resistance patterns, phased role transitions, the training investment decision, and a 90-day scorecard for the work itself.

Sarasota’s marine life faces immediate, lethal and other consequences from plastic. We need a better approach to how we use ...